{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:35:36Z","timestamp":1762076136105,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objective: This paper illustrates the results of a mono-institutional registry trial, aimed to test whether gastrointestinal (GI) and genitourinary (GU) toxicity rates were lower in localized prostate cancer patients treated with image-guided volumetric modulated arc therapy (IG-VMAT) compared to those treated with IG-3D conformal radiation therapy (IG-3DCRT). Materials and Methods: Histologically proven prostate cancer patients with organ-confined disease, treated between October 2008 and September 2014 with moderately hypofractionated radiotherapy, were reviewed. Fiducial markers were placed in the prostate gland by transrectal ultrasound guide. The prescribed total dose was 70 Gy in 28 fractions. The mean and median dose volume constraints for bladder and rectum as well as total volume of treatment were analyzed as potentially prognostic factors influencing toxicity. The Kaplan\u2013Meier method was applied to calculate survival. Results: Overall, 83 consecutive patients were included. Forty-two (50.6%) patients were treated with 3D-CRT and 41 (49.4%) with the VMAT technique. The median follow-up for toxicity was 77.26 months for the whole cohort. The VMAT allowed for a dose reduction to the rectum and bladder for the large majority of the considered parameters; nonetheless, the only parameter correlated with a clinical outcome was a rectal dose limit V66 &gt; 8.5% for late GI toxicity G \u2265 2 (p = 0.045). Rates of G \u2265 2 toxicities were low among the whole cohort of these patients treated with IGRT. The analysis for rectum dose volume histograms (DVHs) showed that a severe (grade \u2265 2) late GI toxicity was related with the rectal dose limit V66 &gt; 8.5% (p = 0.045). Conclusions: This study shows that moderate hypofractionation is feasible and safe in patients with intermediate and high-risk prostate cancer. Daily IGRT may decrease acute and late toxicity to organs at risk and improve clinical benefit and disease control rate, cutting down the risk of PTV geographical missing. The adoption of VMAT allows for promising results in terms of OAR sparing and a reduction in toxicity that, also given the small sample, did not reach statistical significance.<\/jats:p>","DOI":"10.3390\/jcm11236913","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T02:54:05Z","timestamp":1669258445000},"page":"6913","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prostate Cancer Treatment-Related Toxicity: Comparison between 3D-Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) Techniques"],"prefix":"10.3390","volume":"11","author":[{"given":"Fabrizio","family":"Tonetto","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University General Hospital, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Magli","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University General Hospital, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Moretti","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, University General Hospital, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Emanuele","family":"Guerini","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, ASST Spedali Civili and Brescia University, 25100 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarita","family":"Tullio","sequence":"additional","affiliation":[{"name":"Hygiene and Clinical Epidemiology Unit, University General Hospital, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Reverberi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University General Hospital, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tino","family":"Ceschia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University General Hospital, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8635-7411","authenticated-orcid":false,"given":"Luigi","family":"Spiazzi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, ASST Spedali Civili and Brescia University, 25100 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Titone","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University General Hospital, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Prisco","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University General Hospital, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Andrea","family":"Signor","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University General Hospital, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-1260","authenticated-orcid":false,"given":"Michela","family":"Buglione","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, ASST Spedali Civili and Brescia University, 25100 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gioacchino","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"Department of Urology, University General Hospital, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Trov\u00f2","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University General Hospital, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Triggiani","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, ASST Spedali Civili and Brescia University, 25100 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ijrobp.2008.10.091","article-title":"Higher-than-conventional radiation doses in localized prostate cancer treatment: A me-ta-analysis of randomized, controlled trials","volume":"74","author":"Viani","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1200\/jco.2015.33.7_suppl.4","article-title":"A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer","volume":"33","author":"Michalski","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-Fractionation Sensitivity of Prostate Cancer Deduced from Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: \u03b1\/\u03b2 = 1.4 (0.9\u20132.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.ijrobp.2010.12.040","article-title":"Later outcomes and alpha\/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer","volume":"82","author":"Leborgne","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ijrobp.2014.01.015","article-title":"Risk of late toxicity in men receiving dose-escalated hypofractionated intensity mod-ulated prostate radiation therapy: Results from a randomized trial","volume":"88","author":"Hoffman","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.radonc.2006.12.007","article-title":"Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control","volume":"82","author":"Fonteyne","year":"2007","journal-title":"Radiother. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0360-3016(02)02857-2","article-title":"High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients","volume":"53","author":"Zelefsky","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/cncr.25467","article-title":"Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer","volume":"117","author":"Alicikus","year":"2011","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-717X-4-50","article-title":"Image guided dose escalated prostate radiotherapy: Still room to improve","volume":"4","author":"Martin","year":"2009","journal-title":"Radiat. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1748-717X-9-44","article-title":"Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance","volume":"9","author":"Sveistrup","year":"2014","journal-title":"Radiat. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.ijrobp.2006.10.040","article-title":"Predictors for Rectal and Intestinal Acute Toxicities During Prostate Cancer High-Dose 3D-CRT: Results of a Prospective Multicenter Study","volume":"67","author":"Vavassori","year":"2007","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2009.07.1691","article-title":"A Prospective Phase III Randomized Trial of Hypofractionation Versus Conventional Fractionation in Patients with High-Risk Prostate Cancer","volume":"78","author":"Arcangeli","year":"2010","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): Final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2012.02.049","article-title":"Updated Results and Patterns of Failure in a Randomized Hypofractionation Trial for High-risk Prostate Cancer","volume":"84","author":"Arcangeli","year":"2012","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate Cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary safety results from the CHHiP randomised controlled trial","volume":"13","author":"Dearnaley","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial","volume":"16","author":"Aluwini","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0360-3016(98)00091-1","article-title":"Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer","volume":"41","author":"Zelefsky","year":"1998","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0360-3016(03)00665-5","article-title":"Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer","volume":"57","author":"Fiorino","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys. Biol. Phys."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2008.01.048","article-title":"Evidence of limited motion of the prostate by careful emptying of the rectum as assessed by daily MVCT image-guidance with Helical Tomotherapy","volume":"71","author":"Fiorino","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.radonc.2006.08.007","article-title":"Emptying the rectum before treatment delivery limits the variations of rectal dose\u2013volume parameters during 3DCRT of prostate cancer","volume":"80","author":"Stasi","year":"2006","journal-title":"Radiother. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijrobp.2008.01.004","article-title":"Reduction of Prostate Motion by Removal of Gas in Rectum During Radiotherapy","volume":"72","author":"Ogino","year":"2008","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2007.05.046","article-title":"Adaptive radiotherapy for prostate cancer using kilovoltage con-beam computed tomography: First clinical results","volume":"70","author":"Nijkamp","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys. Biol. Phys."},{"key":"ref_26","first-page":"2325","article-title":"NRG Oncology RTOG 0415: A Randomized Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients with Low-Risk Prostate Cancer","volume":"34","author":"Lee","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys. Biol. Phys."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is alpha\/beta for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys. Biol. Phys."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ijrobp.2007.08.003","article-title":"Impact of image guidance on outcomes after external beam radiotherapy for localized prostate cancer","volume":"70","author":"Kupelian","year":"2008","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mazzeo, E., Triggiani, L., Frassinelli, L., Guarneri, A., Bartoncini, S., Antognoni, P., Gottardo, S., Greco, D., Borghesi, S., and Nanni, S. (2021). How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Ra-diotherapy and Clinical Oncology (AIRO). Cancers, 13.","DOI":"10.3390\/cancers13112702"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"a030411","DOI":"10.1101\/cshperspect.a030411","article-title":"Histopathology of Prostate Cancer","volume":"7","author":"Humphrey","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Russo, G.I., Soeterik, T., Puche-Sanz, I., Broggi, G., Giudice, A.L., De Nunzio, C., Lombardo, R., Marra, G., Gandaglia, G., and on behalf of the European Association of Urology Young Academic Urologists (Prostate Cancer Prostatic Dis., 2022). Oncological outcomes of cribriform histology pattern in prostate cancer patients: A systematic review and meta-analysis, Prostate Cancer Prostatic Dis., in press.","DOI":"10.1038\/s41391-022-00600-y"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2017.10.036","article-title":"Genomic Markers in Prostate Cancer Decision Making","volume":"73","author":"Cucchiara","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajur.2021.05.001","article-title":"Molecular markers of systemic therapy response in urothelial carcinoma","volume":"8","author":"Claps","year":"2021","journal-title":"Asian J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mir, M.C., Campi, R., Loriot, Y., Puente, J., Giannarini, G., Necchi, A., and Roupr\u00eat, M. (Eur. Urol. Oncol., 2021). Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities, Eur. Urol. Oncol., in press.","DOI":"10.1016\/j.euo.2021.04.004"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.2174\/1389450121666200324151056","article-title":"PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay","volume":"21","author":"Cimadamore","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(22)00128-0","article-title":"Nivolumab, nivolumab\u2013ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): A biomarker-driven, open-label, non-comparative, randomised, phase 2 trial","volume":"23","author":"Vano","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_38","first-page":"139","article-title":"Biopsia l\u00edquida y c\u00e1ncer de pr\u00f3stata. Evidencia actual aplicada a la cl\u00ednica","volume":"44","author":"Cubero","year":"2019","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas"},{"key":"ref_39","first-page":"139","article-title":"Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer","volume":"44","author":"Athie","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/pros.24419","article-title":"Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors","volume":"82","author":"Yazgan","year":"2022","journal-title":"Prostate"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/23\/6913\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:25:16Z","timestamp":1760145916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/23\/6913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":40,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["jcm11236913"],"URL":"https:\/\/doi.org\/10.3390\/jcm11236913","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,11,23]]}}}